Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03705884
Other study ID # AC17010
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 30, 2017
Est. completion date December 1, 2018

Study information

Verified date May 2024
Source University of Edinburgh
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

PET scanning (positron emission tomography) is a well-established technique used to identify areas of interest within the body. It involves injecting a radioactive tracer which highlights abnormal areas. It has recently been combined with CT (computed tomography) and MRI (magnetic resonance imaging) scanning to more accurately identify abnormalities within the heart. Cardiac sarcoidosis, a condition which causes scarring and inflammation within the heart muscle, is of particular interest. The study makes use of hybrid PET/MR scanning using a designated scanner which enables PET scanning combined with MRI scanning. This will allow imaging of abnormal areas within the heart in this condition alongside treatment regimens in a way which hasn't been done before. If successful, this imaging method will play a key role in diagnosing, quantifying and monitoring these conditions. All participants will undergo PET scanning, where a radioactive tracer is injected into a vein before the scan. The radioactive substance only lasts for a short time and is safe, passed out of the body in urine. The scan will be performed twice; once before treatment and once after treatment has been established. A cohort of healthy volunteers will undergo scanning in exactly the same way to enable us to compare the results with hearts of people who don't have cardiac sarcoidosis.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date December 1, 2018
Est. primary completion date December 1, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 40 Years and older
Eligibility Inclusion Criteria: Cardiac Sarcoidosis Patients: - Aged over 40 years - Completion of informed consent - Established diagnosis of cardiac sarcoidosis - Established diagnosis as per HRS recommended diagnostic criteria Healthy Volunteers: - Aged over 40 - Completion of informed consent Exclusion Criteria: - All participants: - Inability or unwilling to give informed consent - Women who are pregnant, breastfeeding or of child-bearing potential (women who have experienced menarche, are pre-menopausal and have not been sterilised) will not be enrolled into the trial. - Major intercurrent illness with life-expectancy <2 years. - Renal dysfunction (eGFR less than or equal to 30ml/min/1.73m2) - Adverse reaction or hypersensitivity to 18F-FDG PET tracer - NYHA Class IV heart failure - Patients with atrial fibrillation and poor rate control - Contraindications to MRI scanning - Previous history of contrast allergy of adverse reactions (Gadolinium-containing agents)

Study Design


Related Conditions & MeSH terms


Intervention

Other:
18F-FDG
Hybrid 18F-FDG PET/MR imaging for observational diagnostic purposes.
Drug:
Prednisolone
Oral course of Prednisolone for treatment of sarcoidosis (patient cohort) or as control (healthy volunteer cohort)

Locations

Country Name City State
United Kingdom Queen's Medical Research Institute Edinburgh Midlothian

Sponsors (1)

Lead Sponsor Collaborator
University of Edinburgh

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Myocardial 18F-FDG uptake Quantification of myocardial PET tracer uptake before steroid therapy Within 1 year
Primary Myocardial 18F-FDG uptake Quantification of myocardial PET tracer uptake after steroid therapy Within 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT04017936 - Interleukin-1 Blockade for Treatment of Cardiac Sarcoidosis Phase 2
Recruiting NCT06131112 - Macrophage PET/CT Imaging Using 64Cu-DOTATATE for the Diagnosis of Cardiac Sarcoidosis
Terminated NCT03923049 - Feasibility and Accuracy of Hybrid Magnetic Resonance and Positron Emission Tomography With 18F-Fluorodeoxyglucose in Diagnosing Cardiac Sarcoidosis N/A
Not yet recruiting NCT05954507 - Evaluation of the Prognostic Value of PET/MRI in Cardiac Sarcoidosis N/A
Recruiting NCT06409585 - Cardiomyopathies and Heart Muscle Diseases: Cardiac Imaging in the Evaluation of Myocardial Fibrosis Transition
Recruiting NCT04737317 - Diagnostic Criteria in Cardiac Sarcoidosis
Recruiting NCT03057002 - UTSW HP [13-C] Pyruvate Injection in HCM
Completed NCT03599414 - CASPA: CArdiac Sarcoidosis in PApworth
Withdrawn NCT02812849 - Somatostatin Receptor Imaging in Cardiac Sarcoidosis
Completed NCT01729169 - Cardiac Sarcoidosis: FDG PET vs. Ga-DOTANOC PET N/A
Completed NCT03549598 - d68Ga-DOTATATE PET/CT Assessment of Cardiac Sarcoidosis Phase 4
Recruiting NCT04758650 - Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions, Cardiovascular Atherosclerosis, Syndrome With Abnormal Immune Activation and sarcoïdosis Phase 2
Recruiting NCT04206163 - Somatostatin Receptor Imaging in Acute Myocarditis and Cardiac Sarcoidosis N/A
Recruiting NCT05499637 - [68Ga]Ga-PentixaFor PET/CT in Acute Myocardial Inflammation Phase 2
Recruiting NCT03593759 - Cardiac Sarcoidosis Randomized Trial Phase 3
Recruiting NCT05145023 - Development and Validation of a Health-related Quality of Life Tool for Patients With Cardiac Sarcoidosis
Enrolling by invitation NCT04774549 - Inflammatory Cardiomyopathy Bern Registry
Recruiting NCT03049254 - Mayo AVC Registry and Biobank
Completed NCT03746847 - PET Imaging in Patients With Suspected Cardiac Sarcoidosis
Recruiting NCT01477359 - Cardiac Sarcoidosis Multi-Center Prospective Cohort